Professional Documents
Culture Documents
Diabetes Drugs PDF
Diabetes Drugs PDF
-blocks K channel in the -for Type 2 diabetics -GI distress -not to be used w/ renal or liver impaired
Sulfonylureas membrane of pancreatic ß cells; -dizziness, drowsiness, HA patients
depolarizes cell & stimulates 2nd generation: -allergies—skin rxs DDIs: sulfonamides, salicylates,
Incr.
1st gen: tolbutamide (ORINASE) release of insulin -fewer side effects -hypoglycemia phenylbutazon : hypoglycemia
nd
2 gen: glipizide -may also decr. hepatic glucose -more predictable action times &
-weight gain -thiazides: hyperglycemic activity
(GLUCOTROL) half-lives
production (glyconolysis and -fewer DDIs-bind to proteins -beta-adrenergic blocking agents
INSULIN
Insulin Enhancers -promotes insulin secretion by the -for type 2 diabetics -hypoglycemia -patients must eat w/i 30 minutes of
pancreas administration
Repanglinide, (PRANDIN)
SECRETION
- decr. hepatic glucose -for treatment of type 2 -GI effects—anorexia, -Avoid in patients w/ severe liver or
Decr. Glucose production
production diabetes, alone or w/ a flatulence, metallic taste, renal dx, cardiorespiratory insufficiency,
Biguanides - incr. peripheral insulin sulfonylurea N/V, stomach pain, weight CHF
sensitivity esp. in muscle tissue -does not cause loss DDIs: avoid alcohol—hypoglycemic
Metformin hypoglycemia-an - Weight loss cimetidine, digoxin, morphine, rantidine,
(GLUCOPHAGE) antihyperglycemic drug - Decr. absorption of trimethorprim, furosemide,
vitamin B12 and folic acid vancomycin—incr. blood concentration
of metformin
-prolongs digestion of CHO -for treatment of type 2 -GI: flatulence, abdominal -used as mono or combo therapy w/
Stop Gut N-Zymes
Alpha-glucosidase -decr. peak plasma glucose levels diabetes pain, distenion, diarrhea, sulfonylureas
inhibitors by inhibiting intestinal enzymes borborygmi -TID w/ first bite of food
in SI that break complex -Incr. in liver enzymes -SE diminish w/ time—usually 3 wks
aka “starch-blockers”
acarabose (PRECOSE)
miglitol (GLYSET) carbohydrates into smaller DDIs: corticosteroids & thiazides—
molecules interfere w/ control of hyperglycemia
Drug Action Use Side Effects Nursing Implications
Decr. insulin resistance
-acts on target tissues to decr. insulin -for treatment of type 2 -edema, weight gain -cytochrome P450 inducer so check
Thiazolidinediones liver function: 1st six months-check
resistance in skeletal muscle diabetes; mono or combo -anemia
(Glitazones) monthly; 2nd six months-check
-may also decr. glucose output by the therapy
rosiglitazone (AVANDIA) liver every 2 months
pioglitazone (ACTOS) -teach patient of liver failure signs
DDIs: Ca channel blocking agents
corticosteroids, statins and BC pills
BLOOD GLUCOSE
LOWERING EFFECTS